Soleno Therapeutics presents new Vykat XR data at ENDO

San Diego, USA-based Soleno Therapeutics, which has just been acquired by Neurocrine Biosciences (Nasdaq: NBIX), has announced late-breaking data at ENDO 2026 showing that resuming treatment with Vykat XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms characteristic of Prader-Willi syndrome (PWS).

"These compelling data further reinforce our confidence in Vykat XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome," said Dr Sanjay Keswani, chief medical officer, Neurocrine Biosciences, adding: “Individuals who resumed treatment following the randomized withdrawal period achieved durable improvements in hyperphagia and other PWS-related behaviors. This completes the presentation of data from our comprehensive Phase III development program and further confirms the long-term benefit of Vykat XR for people living with PWS."